Pfizer’s (PFE) performance in 2025 so far has been weighed down by weak demand for its COVID products. Meanwhile, growth in its non-COVID portfolio, especially oncology, has helped offset some of the decline. Further, the $10 billion Metsera acquisition strengthens the pharma giant’s future, opening doors to the fast-growing weight-loss market. Moreover, Pfizer stock is a Strong Buy, according to the technical indicators, implying further upside from current levels.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Analyzing PFE Stock’s Technical Indicators
According to TipRanks’ easy-to-understand technical analysis tool, Pfizer stock is currently on an upward trend. The stock’s 50-day Exponential Moving Average (EMA) is 24.54, while its price is $25.45, implying a bullish signal. Further, its shorter-duration EMA (20 days) also signals a Buy.
Another technical indicator, Williams %R, helps traders see if a stock is overbought or oversold. For PFE stock, Williams %R currently shows a Buy signal, suggesting the stock is not overbought and has room to run.
Moreover, the Rate of Change (ROC) is a momentum-based technical indicator. It measures the percentage change in a stock’s price between the current price and the price from a specific number of periods ago. Typically, an ROC above zero confirms an uptrend. Pfizer currently has an ROC of 6.62, which signals a Buy.
Is Pfizer a Buy, Sell, or Hold?
Turning to Wall Street, PFE stock has a Hold consensus rating based on four Buys, 10 Holds, and one Sell assigned in the last three months. At $29.08, the average Pfizer stock price target implies a 16.65% upside potential.
